文献速递白血病

低剂量阿糖胞苷联合来那度胺对比单用低剂量阿糖胞苷在老年急性髓系白血病患者中的随机评估:LI-1试验结果

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
PubMed 文献 · Br J Haematol · 2023-11-28

LI-1试验纳入202例年龄>60岁、不适合强化治疗的急性髓系白血病患者,1:1随机接受低剂量阿糖胞苷联合来那度胺或单用低剂量阿糖胞苷。联合组总缓解率(CR+CRi)高于单药组(26% vs 13.7%,p=0.031),但两组2年总生存率无差异(14% vs 11.5%)。加用来那度胺与毒性及支持治疗需求增加相关。

要点

  • 联合组总缓解率(CR+CRi)26% vs 单药组13.7%(p=0.031)。
  • 两组2年总生存率无差异:联合组14% vs 单药组11.5%。
  • 加用来那度胺与毒性及支持治疗需求增加相关。

核心结论

  • 在年龄>60岁、不适合强化治疗的急性髓系白血病患者中,低剂量阿糖胞苷联合来那度胺较单用低剂量阿糖胞苷提高了总缓解率,但未改善总生存,且毒性及支持治疗需求增加。

研究设计与样本

  • LI-1试验的随机对照研究,202例年龄>60岁、不适合强化治疗的急性髓系白血病患者按1:1随机分配接受低剂量阿糖胞苷联合来那度胺或单用低剂量阿糖胞苷。

主要发现

  • 总缓解率(CR+CRi)联合组为26%,单药组为13.7%(p=0.031)。
  • 2年总生存率联合组为14%,单药组为11.5%,两组间无差异。
  • 加用来那度胺与毒性增加及支持治疗需求增加相关。

关键数值与推荐

  • 总缓解率(CR+CRi):低剂量阿糖胞苷联合来那度胺组26% vs 单用低剂量阿糖胞苷组13.7%(p=0.031)。
  • 2年总生存率:联合组14% vs 单药组11.5%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Copland M, Ariti C, Thomas IF, et al. A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. Br J Haematol. 2023. PMID: 38016651. doi:10.1111/bjh.19220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。